

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 22 June 2001 (22.06.01)	
International application No. PCT/EP00/08837	Applicant's or agent's file reference 0099350-WSmi
International filing date (day/month/year) 11 September 2000 (11.09.00)	Priority date (day/month/year) 23 September 1999 (23.09.99)
Applicant DÜCKER, Klaus et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

27 March 2001 (27.03.01)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Charlotte ENGER Telephone No.: (41-22) 338.83.38
---	---

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

REC'D 21 JAN 2002

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)


4

Applicant's or agent's file reference 0099350-WSmi	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP00/08837	International filing date (day/month/year) 11/09/2000	Priority date (day/month/year) 23/09/1999
International Patent Classification (IPC) or national classification and IPC C12N15/56		
Applicant MERCK PATENT GMBH et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.
- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
- These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 27/03/2001	Date of completion of this report 17.01.2002
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer SCHEFFZYK, I Telephone No. +49 89 2399 8602



THIS PAGE BLANK (USPIC,

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/08837

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-32 as originally filed

Claims, No.:

1-11 as originally filed

Drawings, sheets:

1/2-2/2 as originally filed

Sequence listing part of the description, pages:

1-41, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/08837

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	2,3,5
	No:	Claims	1,4,6-11
Inventive step (IS)	Yes:	Claims	2,3,5
	No:	Claims	1,4,6-11
Industrial applicability (IA)	Yes:	Claims	1-11
	No:	Claims	

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

THIS PAGE BLANK (USP 10)

SECTION V-----

With respect to the term "fragment" used in claims 1 and 4 it is noted that this term even covers individual amino acid residues and nucleotides, respectively. Correspondingly, claims containing said expression cannot be considered to be novel. In addition, claims 1 and 4 also embrace variants of the sequences recited in these claims. Due to said term any readily available polypeptide and nucleic acid molecule is encompassed by these claims, in particular taking into account that neither claim 1 nor claim 4 requires any function/activity of the claimed product! Correspondingly, claims containing the term "variant" cannot be considered to be novel.

Moreover, even in the absence of the above-objected terms claims 1 and 4 still would be open to objections under Art. 33(2) PCT:

Claim 1, part (b) fails to specify the length of the region of SEQ.ID.NO. 2 to which the claimed polypeptide should be at least 95% identical. In addition, claim 1 fails to require any particular function of the claimed polypeptide. Thus, claim 1(b) embraces any readily available polypeptide and thus lacks novelty. The same reasoning applies also to claim 1(c) which also fails to indicate a function of the claimed polypeptide and, in addition, to require that the complete sequence must be 95% identical to the complete sequence shown in SEQ.ID.NO. 2.

The same applies correspondingly to claim 4(a)-(d) and (f).

As regards claim 4(e) it is noted that a fragment of SEQ.ID.NO. 1 is taught in Database EMBL AC A1222323 (1) (99% identical with SEQ.ID.NO. 1 in 121 nt overlap). In addition, Hpa1 (which has an overall identity of 35% to Hpa2 based on the amino acid sequence) also has nucleotide stretches of more than 15 nucleotides which are identical to Hpa 2. Correspondingly, novelty of claim 4(e) cannot be acknowledged either.

In so far as claims 6-11 contain a reference to claims 1 and 4 novelty of these claims cannot be acknowledged either.

Thus, claims 1, 4, 6-11 do not meet the requirements of Art. 33(2)(3) PCT.

Claims 2,3 and 5 appear to be novel and inventive since the existence of the sequences shown in SEQ.ID.NOS. 1 and 2 was neither taught nor derivable from the documents cited in the ISR.

THIS PAGE BLANK (USPTO)

SECTION VII-----

- 1). Claim 4(d) seems to be identical to claim 4(c). Correspondingly, it is redundant. Relating to this it is noted that the term "having" has the same meaning as the term "comprising".
- 2). Claim 6 should be checked: the word "system" should be replaced by "vector". The word "system" even may encompass human beings which are excluded from patentability.

SECTION VIII-----

- 1). Claim 1 is ambiguous since it is unclear whether said claim relates to a method for screening compounds or to a method of producing a compound (see claim 11, part (f)) (cf. Guidelines C-III 4.1 PCT).
- 2). For the sake of clarity the term "sequence" should be incorporated in claim 5(a) and (b) ("....the polynucleotide sequence of SEQ.ID.NO. 1").

THIS PAGE BLANK (SPT0)

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 0099350-WSmi	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 00/ 08837	International filing date (day/month/year) 11/09/2000	(Earliest) Priority Date (day/month/year) 23/09/1999
Applicant MERCK PATENT GMBH		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

HEPARANASE-2, A MEMBER OF THE HEPARANASE PROTEIN FAMILY

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

1
☐ None of the figures.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

National Application No.

PCT/EP 00/08837

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/56 C12N15/62 C12N9/24 C07K16/40 C12Q1/68
A61K38/47 A61K48/00 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, STRAND, EMBL, BIOSIS, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 43830 A (FAIRBANKS MICHAEL B ; HEINRIKSON ROBERT L (US); MILDNER ANA M (US);) 2 September 1999 (1999-09-02) the whole document	4
Y	page 9, line 13-18	1-11
X	KOSIR M A ET AL.: "Degradation of basement membrane by prostate tumor heparanase" JOURNAL OF SURGICAL RESEARCH, vol. 81, no. 1, January 1999 (1999-01), pages 42-47, XP002155606	1-3
Y	abstract page 45, right-hand column, line 13 -page 46, left-hand column, line 18	4-11
	--- -/-- ---	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

19 December 2000

Date of mailing of the international search report

05/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

van de Kamp, M

INTERNATIONAL SEARCH REPORT

Initial Application No

PCT/EP 00/08837

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KOSIR M A ET AL.: "Human prostate carcinoma cells produce extracellular heparanase" JOURNAL OF SURGICAL RESEARCH, vol. 67, no. 1, January 1997 (1997-01), pages 98-105, XP002155605	1-3
Y	abstract page 102, right-hand column, line 23 -page 103, left-hand column, line 15	4-10
X	DATABASE EMBL 'Online! EMBL; ID AI222323, AC AI222323, 30 November 1998 (1998-11-30) STRAUSBERG R: "qg97h02.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1843155 3', mRNA sequence" XP002155607	4
Y	Note: 99 % nt seq ident with SEQ ID NO:1 in 121 nt overlap. the whole document	1-11
X	WO 99 11798 A (HADASIT MED RES SERVICE ;PECKER IRIS (IL); FEINSTEIN ELENA (IL); F) 11 March 1999 (1999-03-11)	4
Y	the whole document page 17, line 4-20	1-11
X	WO 99 21975 A (HAMDORF BRENTON JAMES ;UNIV AUSTRALIAN (AU); FREEMAN CRAIG GEOFFRE) 6 May 1999 (1999-05-06)	4
Y	the whole document page 13, line 4-9	1-11
T	MCKENZIE E ET AL.: "Cloning and expression profiling of hpa2, a novel mammalian heparanase family member" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 276, no. 3, 5 October 2000 (2000-10-05), pages 1170-1177, XP002155087 Note: 99.8 % nt seq ident with SEQ ID NO:1 in 1779 nt overlap, 99.7 % aa seq ident with SEQ ID NO:2 in 592 aa overlap. the whole document page 1175, right-hand column, line 2-4	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/08837

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9943830 A	02-09-1999	AU 2759199 A	15-09-1999
WO 9911798 A	11-03-1999	US 5968822 A	19-10-1999
		AU 9125898 A	22-03-1999
		CN 1272886 T	08-11-2000
		EP 0998569 A	10-05-2000
		NO 996228 A	28-02-2000
		US 6153187 A	28-11-2000
WO 9921975 A	06-05-1999	AU 1010999 A	17-05-1999
		BR 9813296 A	22-08-2000
		EP 1032656 A	06-09-2000
		ZA 9809824 A	24-06-1999

THIS PAGE BLANK (USPTO)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/21814 A1

(51) International Patent Classification⁷: C12N 15/56,
15/62, 9/24, C07K 16/40, C12Q 1/68, A61K 38/47, 48/00,
G01N 33/50

(72) Inventors; and

(75) Inventors/Applicants (for US only): DÜCKER, Klaus
[DE/DE]; Ettesterstrasse 5, 64291 Darmstadt (DE). SIR-
RENBURG, Christian [DE/DE]; Heinrich-Delp-Strasse
221, 64297 Darmstadt (DE).

(21) International Application Number: PCT/EP00/08837

(22) International Filing Date:
11 September 2000 (11.09.2000)

(74) Common Representative: MERCK PATENT GMBH;
64271 Darmstadt (DE).

(25) Filing Language: English

(81) Designated States (national): CA, JP, US.

(26) Publication Language: English

(84) Designated States (regional): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).


(30) Priority Data:
99118805.3 23 September 1999 (23.09.1999) EP
00114649.7 7 July 2000 (07.07.2000) EP

Published:
— With international search report.

(71) Applicant (for all designated States except US): MERCK
PATENT GMBH [DE/DE]; Frankfurter Strasse 250,
64293 Darmstadt (DE).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HEPARANASE-2, A MEMBER OF THE HEPARANASE PROTEIN FAMILY



(57) Abstract: Heparanase-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing heparanase-2 polypeptides and polynucleotides in diagnostic assays.

THIS PAGE BLANK (USPTO)

HEPARANASE-2, A MEMBER OF THE HEPARANASE PROTEIN FAMILY

Field of the Invention

5 This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides sometimes hereinafter referred to as „heparanase-2“, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

10 **Background of the Invention**

The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding
15 earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on high-throughput DNA sequencing
20 technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

25

Summary of the Invention

The present invention relates to heparanase-2, in particular heparanase-2 polypeptides and heparanase-2 polynucleotides, recombinant materials and methods for their production. Such polypeptides and polynucleotides
30 are of interest in relation to methods of treatment of certain diseases, including, but not limited to, autoimmune disorders, blood coagulation

disorders, cancer, diabetes, ischemia, sepsis and stroke, cardiovascular diseases, thrombosis, hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with heparanase-2 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate heparanase-2 activity or levels.

10 Description of the Invention

In a first aspect, the present invention relates to heparanase-2 polypeptides. Such polypeptides include:

- (a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1;
- 15 (b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- (c) an isolated polypeptide comprising the polypeptide sequence of SEQ ID NO:2;
- 20 (d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- (e) the polypeptide sequence of SEQ ID NO:2; and
- (f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2;
- 25 (g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the endoglucuronidase family of polypeptides. Heparan sulfate proteoglycans (HSPGs) are ubiquitous macromolecules of cell surfaces, basement membranes and the extracellular matrix (ECM). They play a major role in cell-cell and cell-extracellular matrix interactions. HSPGs

have been reported to bind to a variety of different molecules like growth factors (e.g. fibroblast growth factors and platelet-derived growth factor), cytokines (e.g. interleukin-2), extracellular matrix proteins (e.g. fibronectin, laminin, collagen), factors involved in blood coagulation (e.g. antithrombin III), and other proteins such as lipoproteins, DNA topoisomerases, and α -amyloid proteins (Kjellen, L. and Lindahl, U., Annu. Rev. Biochem. 60, 443-475 (1991); Wight, T.N. et al., Curr. Opin. Cell Biol. 4, 793-801 (1992)).

Binding of signalling molecules to HSPGs leads to their sequestration, thereby creating a localised, readily accessible depot of these bound molecules, which can easily be released upon degradation of HSPGs (Nissen, N. et al., Biochem. J. 338, 637-642 (1999)). Additionally HSPGs are important structural components of the ECM. In capillaries they are found mainly in the subendothelial basement membrane, where they support the vascular endothelium and stabilise the structure of the capillary wall. Expression of heparan sulfate (HS)-degrading endoglucuronidases, commonly called 'heparanases' (Nakajima, M. et al., J. Biol. Chem. 259, 2283-2290 (1984)), is found in blood borne cells and placental trophoblasts, reflecting their requirement for cell diapedesis activity associated with inflammatory processes or wound healing, and pregnancy, respectively (Vlodavsky, I. et al., Invasion Metastasis 12, 112-127 (1992); Goshen, R. et al., Mol. Hum. Reprod. 2, 679-684 (1996)).

Degradation of the HS moieties of HSPGs affects a great variety of biological processes. Of particular interest is the proposed function of heparanases in neoangiogenesis and metastasis, associated with malignant tumours. It has been shown that secreted heparanase activity induces endothelial mitogenesis (Folkman, J. et al., Am. J. Pathol. 13, 393-400 (1988); Ishai-Michaeli, R. et al., Cell. Regul. 1, 833-842 (1990)) and is directly correlating with the metastatic property of a number of human metastatic cell lines as well as specimens of human breast, colon and liver carcinomas (Nakajima, M. et al., Science 220, 611-613 (1983); Vlodavsky, I. et al., Cancer Res. 43, 2704-2711 (1983)).

Biochemical experiments identified so far three distinct groups of heparanase activities, with molecular weights of 137 kDa (Oosta, H.G.M.

et al., J. Biol. Chem. 257, 11249-11255 (1982)), 50 kDa (Freeman, C. and Parish, C.R., Biochem. J. 330, 1341-13509 (1998)), and 32-40 kDa (Hoogewerf, A.J. et al., J. Biol. Chem. 270, 3268-3277 (1995)). The first mammalian heparanase gene representing the 50 kDa class (Vlodavsky, I. et al., Nat. Medicine 5, 793-802 (1999); Hulett, M.D. et al., Nat. Medicine 5, 803-809 (1999); Toyoshima M. and Nakajima M., J. Biol. Chem. 270, 24153-24160 (1999)). The heparanase gene is preferentially expressed in highly metastatic mouse and human cell lines and in biopsy specimen of human tumours. Moreover, increased levels of heparanase were detected in sera (Nakajima, M. et al., Science 220, 611-613, (1983)) and urine of metastatic tumour-bearing animals and cancer patients (Vlodavsky, I. et al., Nat. Medicine 5, 793-802 (1999)). Transfection of low or non-metastatic tumour cell lines with the heparanase gene confers a high metastatic potential in experimental mice, resulting in an increased rate of mortality. On the contrary, treatment of experimental animals with heparanase inhibitors (e.g., non-anticoagulant species of low-molecular-weight heparin and polysulfated saccharides) considerably reduces the incidence of lung metastases by melanoma, Lewis lung carcinoma and mammary adenocarcinoma cells (Vlodavsky I. et al., Invasion Metastasis 14, 290-302 (1995), Parish, C.R. et al., Int. J. Cancer 40, 511-517 (1987)). As it is generally accepted that heparanase activity plays a crucial role in many distinct biological processes, there is a clear need to identify further members of this protein family

The biological properties of the heparanase-2 are hereinafter referred to as "biological activity of heparanase-2" or "heparanase-2 activity". Preferably, a polypeptide of the present invention exhibits at least one biological activity of heparanase-2.

Polypeptides of the present invention also includes variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO: 2. Preferred fragments are biologically active fragments that mediate the biological activity of heparanase-2, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesizers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to heparanase-2 polynucleotides. Such polynucleotides include:

- (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide sequence of SEQ ID NO:1;
- (b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1;

(c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide of SEQ ID NO:1;

(d) the isolated polynucleotide of SEQ ID NO:1;

5 (e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;

(f) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2;

10 (g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;

(h) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2;

15 (i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polynucleotide sequence of SEQ ID NO:1;

(j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2; and

20 polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

25 Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from the sequence of SEQ ID NO: 1, or an isolated polynucleotide comprising an sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from the sequence of SEQ ID NO: 1.

30 Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including

polynucleotides having one or more single nucleotide polymorphisms (SNPs).

Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

(a) comprises an RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2;

(b) is the RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2;

(c) comprises an RNA transcript of the DNA sequence of SEQ ID NO:1; or

(d) is the RNA transcript of the DNA sequence of SEQ ID NO:1;

and RNA polynucleotides that are complementary thereto.

The polynucleotide sequence of SEQ ID NO:1 shows homology with AF144325 (Vlodavsky, I. et al., Nat. Medicine 5, 793-802(1999)). The polynucleotide sequence of SEQ ID NO:1 is a cDNA sequence that encodes the polypeptide of SEQ ID NO:2. The polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence of SEQ ID NO:1 or it may be a sequence other than SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of the SEQ ID NO:2 is related to other proteins of the endoglucuronidase family, having homology and/or structural similarity with AAD42342 (Vlodavsky, I. et al., Nat. Medicine 5, 793-802(1999)).

Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one heparanase-2 activity.

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA in cells of human bladder, (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence of SEQ ID NO:1, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic

clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof, preferably of at least 15 nucleotides.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-

9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al. (*ibid*). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic

interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 in the cDNA or genomic sequence and which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled heparanase-2 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising heparanase-2 polynucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well

known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M.Chee et al., Science, 274, 610-613 (1996) and other references cited therein.

5 Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

- 20 (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment or an RNA transcript thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof; or
- 25 (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

30

The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequence is specifically targeted to,

and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has
5 been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been
10 mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P.,
15 (1994) A method for constructing radiation hybrid maps of whole genomes, Nature Genetics 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (Hum Mol Genet 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH
20 DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at
25 <http://www.genome.wi.mit.edu/>.
30

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded
35 polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include in situ hybridisation techniques to clones arrayed on a grid, such as cDNA microarray

hybridisation (Schena *et al*, Science, 270, 467-470, 1995 and Shalon *et al*, Genome Res, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

The polypeptides of the present invention are expressed in blood cells, cancer tissues, fetal liver, lymph nodes, placenta, spleen, trophoblast cells.

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic

mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation instonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier

immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule.

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (e.g. agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring a heparanase-2 activity in the

mixture, and comparing the heparanase-2 activity of the mixture to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek et al, Anal Biochem., 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and heparanase-2 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

Screening techniques

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete

with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and heparanase-2 gene. The art of constructing transgenic animals is well established. For example, the heparanase-2 gene may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;

- (c) a cell membrane expressing a polypeptide of the present invention; or
- (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

Glossary

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

10 "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an

Fab or other immunoglobulin expression library.

15 "Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover,
20 a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

25 "Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxribonucleotide (DNA), which may be unmodified or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules
30 comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In

addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation,

gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol, 182, 626-646, 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci, 663, 48-62, 1992).

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence of SEQ ID NO:1..

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a

variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

"Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

"Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

"Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by

comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

5 "% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity
10 may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

15 "Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of
20 the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

25 Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the
30 programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147,195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the
35 best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide

sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Needleman and Wunsch (J Mol Biol, 48, 443-453, 1970).
5 GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and
10 similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F
15 et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat
20 Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide
25 sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the
30 reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate
35 polynucleotide sequence having, for example, an Identity Index of 0.95

5 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as
10
15 hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

35 The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \bullet I),$$

in which:

n_a is the number of nucleotide or amino acid differences,

x_a is the total number of nucleotides or amino acids in SEQ ID NO:1 or
5 SEQ ID NO:2, respectively,

I is the Identity Index ,

\bullet is the symbol for the multiplication operator, and

in which any non-integer product of x_a and I is rounded down to the nearest integer prior to subtracting it from x_a .

10 "Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are
15 the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

"Fusion protein" refers to a protein encoded by two, unrelated, fused
20 genes or fragments thereof. Examples have been disclosed in US 5541087, 5726044. In the case of Fc-heparanase-2, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for performing the functional expression of Fc-heparanase-2 or fragments of heparanase-2, to improve pharmacokinetic properties of such a fusion
25 protein when used for therapy and to generate a dimeric heparanase-2. The Fc-heparanase-2 DNA construct comprises in 5' to 3' direction, a secretion cassette, i.e. a signal sequence that triggers export from a mammalian cell, DNA encoding an immunoglobulin Fc region fragment, as a fusion partner, and a DNA encoding heparanase-2 or fragments
30 thereof. In some uses it would be desirable to be able to alter the intrinsic functional properties (complement binding, Fc-Receptor binding) by mutating the functional Fc sides while leaving the rest of the fusion protein untouched or delete the Fc part completely after expression.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

Figures

Figure.1

Quantification of the relative in vivo expression of (Heparanase-2) Hep-2 using a real-time quantitative reverse transcription-polymerase chain reaction (Taq-Man).

Figure. 2

Hep-2 is expressed in various tumor tissue. A real-time quantitative reverse transcription-polymerase chain reaction was used to quantify the relative expression of Heparanase-2 (normalized to β -actin).

Figure. 3

Expression of Heparanase-2 (Hep-2) in 293 human kidney fibroblastys.

Western blot analysis using anti-V5-HRP antibodies. Lane1 (control), cell lysate of 293 cells transiently transfected with pcDNA3/TRAF-His; lane 2 (β -gal), cell lysate of 293 cells transiently transfected with pcDNA3.1/lacZ-V5-His; lane 3 (Hep-2), cell lysate of 293 cells transiently transfected with pcDNA3.1/Hep-2-V5-His.

Further examples

Example 1

RT-PCR

in vivo expression has been evaluate using real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR). As RT-PCR assay the Taq-Man fluorescence methodology (ABI PRISM 7700 Sequence detection system) was used. To quantify the relative expression of Heparanase-2 the upstream primer 5'-CCGATTCCTATGCTGCAGGA-3' and the downstream primer 5'- TCACGACATCAATGCCCTGA-3' and the fluorescence-labeled probe (6-carboxyfluorescein, 6-carboxy-tetramethyl-rhodamine);

5'CTTATGGTTGAACACTTTAGGAATGCTGGCC-3' have been used. All reactions were done in a 96 well-plate with 40 PCR-cycles (according ABI PRISM 7700 SDS). Typical used PCR-cycles: 1x 50°C 2min, 1x 95°C 10min, 40x 95°C and 15sec 60°C 1min.

The relative mRNA-expression was normalized to α -actin using the upstream primer 5'-ATTGCCGACAGGATGCAGAA-3', the downstream primer 5'-TTCCAGCAGATGTGGATCAGC-3' and the fluorescence-labeled probe (6-carboxyfluorescein, 6-carboxy-tetramethylrhodamine) 5'-CAAGATCATTGCTCCTCCTGAGCGCA-3'.

RNA and cDNA were obtained from Analytical Biological Services Inc. (aorta, bone marrow, colon, corpus C., lymph node, ovary, spinal cord, stomach), Clontech, Heidelberg, (brain, heart, kidney, skeletal muscle, testis, uterus, prostate, pancreas, liver) and Invitrogen, Netherland, (tumor tissue).

Example 2

Cloning and expression of Heparanase-2

The cDNA was generated from total prostate RNA (Clontech, Heidelberg) according to the SMART race cDNA amplification kit (#K1811-1, Clontech). Heparanase-2 DNA was amplified from the cDNA by the polymerase chain reaction (PCR) using the upstream primer1 5'-GCGAGACCCAGTAGGAAGAGAGG-3' and the downstream primer1 5'CAGCAGGCCCACTGGTAGCCAT-3'.

Typical PCR-cycles :5 cycles 94°C 5 sec, 72°C 3min, 5 cycles 94°C 5 sec, 70°C 10sec, 72°C 3min, 20 cycles 94°C 5 sec, 68°C 10 sec, 72°C 3 min.

5 The PCR-product was further amplified using the upstream primer2 5'-ATGAGGGTGCTTTGTGCCTTCCC-3' and the downstream primer3 5'-TCGGTAGCGGCAGGCCAAAGCA-3' according to the SMART race cDNA amplification kit (#K1811-1, Clontech). Typical PCR-cycles: 25 cycles 94°C 5 sec, 68°C 10 sec, 72°C 3 min

10 The PCR fragment was cloned into pcDNA3.1/V5-His TOPO TA vector (#K4800-01, Invitrogen), sequenced using the BigDye-Kit (Applied Biosystems, Weiterstadt; ABI Prism 310 Genetic Analyzer) and used to transfect human 293 cells (ATCC, Rockville, Maryland) with the SuperFect transfection reagent (#301305, Qiagen) according to the protocol for transient transfection of adherent cells (Qiagen). After 24h
15 cells were lysed for 15 min in lysis buffer (50mM Tris pH 7,5; 10% NP40, 0,15% Deoxycholat, 1mM EDTA, 1µg/ml Aprotinin und Leupeptin, 1mM PMSF), centrifuged for 10 min at 20000xg and loaded on a Novex Mini-Gel (#EI0001, Invitrogen). After transfer on Nitrocellulose (X cell blot module #EI9051, Invitrogen) the exprressed Hep-2-V5-His fusion protein.
20 was detected using an anti-V5-HRP antibody (#R961-25, Invitrogen). A vector containing LacZ-V5-His (Invitrogen) and a pcDNA3/His vector containing TRAF (Acc.No. Q13077) were used as controls.

Example 3

25 Production of Heparanase-2

Cells expressing Heparanase with a C-terminal histidin tag were lysed in lysis buffer (20mM Tris pH 7,5; 150 mM NaCl, 1% TX-100, 0,25% NP40, 0,15% Deoxycholat, 1µg/ml Aprotinin, 1µg/ml Leupeptin, 1mM PMSF). The expressed protein was purified using chelators such as NTA or imido
30 acetic acid immobilized on a colum matrix and modified with metall ions such as Co, Ni, or Cu. The expressed protein was detected by western blotting method using anti-His6 antibody (Qiagen/ Invitrogen).

Example 4

Heparanase-2 activity

Heparanase activity can be measured toward fluorescein isothiocyanate (FITC)-heparan sulfate (HS). One milligram of heparan sulfate (Sigma) and 1 mg of FITC (Molecular probes, Oregon) were dissolved in 200 µl of 0,1 M sodium carbonate buffer, pH 9,5, and stirred overnight at 4 °C. The solution was then further loaded on a PD-10 desalting column (Pharmacia) to isolate FITC-HS. The cell lysate (example 2) was added to the reaction mixture (50mM sodium acetate, pH 4,2 containing FITC-HS) and incubated for 18h at 37°C. The reaction was stopped by the addition of Heparin (Sigma). The products of FITC-HS yielded by this reaction were analyzed by gel chromatography (Amersham Pharmacia).

Example 5

15 Production of Heparanase-2 specific antibodies

Heparanase-2 purified using PAGE electrophoresis (Laemmli, 1970) is used to immunize rabbits for the production of antibodies using standard protocols.

20 The amino acid sequence translated from Hep-2 is analyzed using DNASTar software (DNASTar Inc) to determine regions of high immunogenicity. Synthetic peptides have been synthesized (amino-acid sequence 156-169 (VALDK QKGCK IAQH), 249-262 (ASKKY NISWE LGNE), 505-518(HRSRK KIKLA GTLR)) and used to raise antibodies using standard protocols.

25 The oligopeptides are 15 residues in length, and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS, Pierce). Rabbits are immunized with the oligopeptide-KLH complex in complete Freud's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by
30 binding the peptide to nitrocellulose, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with goat anti-rabbit-HRP (Biorad). High titered immune sera generated with the recombinant protein or synthetic peptide have been used to established ELISA technology and

Western blot technique to monitor and quantitate the recombinant protein. Generally antibodies of a given specificity have been pooled and precipitated with Ammonium-sulfate and dialysed against PBS. Selected sera have been biotinylated using the NHS-ester derivative of the biotin, available via Pierce. Biotinylation was performed according to the manufacturer. The antigens and the immunochemical techniques used to rise and characterize the polyclonal antibodies can easily be extended with protocols used for the production of monoclonal antibody specificities. The expert in this field would make his choice between a classical technique such as the hybridoma based technology or an antibody library based method according to his individual possibilities.

Example 6

Immuno-Assays for estimation of Heparanase-2

Specific sera raised with recombinant heparanase-2 have been used as a „catcher antibody“ for the coating of 96-well micro-titer plates (Nunc). 100 ml of the anti-Heparanase-2 serum (20µg/ml) has been used to coat plates over night. Prior to use, the plates have been washed three times with PBS and have been incubated for one hour with a BSA solution (1%) in order to prevent unspecific binding. Surplus of blocking solution has been removed and 100 µl of Heparanase-2 has been added in serial delutions and has been incubated for one hour. Plates have been washed three times prior to the application of the biotinylated anti-Heparanase-2 antibody for detection. After one hour, read-out has been performed via streptavidin-POD colour reaction with substrates such as ODB-tablets (Dako) measured at 490 nm.

Claims

1. An isolated polypeptide selected from one of the groups consisting of:

(a) an isolated polypeptide encoded by a polynucleotide comprising thesequence of SEQ ID NO:1;

5 (b) an isolated polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

c) an isolated polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2; and

d) the polypeptide sequence of SEQ ID NO:2 and

10 (e) fragments and variants of such polypeptides in (a) to (d).

2. The isolated polypeptide as claimed in claim 1 comprising the polypeptide sequence of SEQ ID NO:2.

15 3. The isolated polypeptide as claimed in claim 1 which is the polypeptide sequence of SEQ ID NO:2.

4. An isolated polynucleotide selected from one of the groups consisting of:

(a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO:1;

20 (b) an isolated polynucleotide having at least 95% identity to the polynucleotide of SEQ ID NO:1;

(c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

25 (d) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

(e) an isolated polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof having at least 15 nucleotides;

5 (f) a polynucleotide which is the RNA equivalent of a polynucleotide of (a) to (e);

or a polynucleotide sequence complementary to said isolated polynucleotide

10 and polynucleotides that are variants and fragments of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

5. An isolated polynucleotide as claimed in claim 4 selected from the group consisting of:

15 (a) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1;

(b) the isolated polynucleotide of SEQ ID NO:1;

(c) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2; and

20 (d) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2.

6. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.

25

7. A recombinant host cell comprising the expression vector of claim 6 or a membrane thereof expressing the polypeptide of claim 1.

8. A process for producing a polypeptide of claim 1 comprising the step of culturing a host cell as defined in claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

5

9. A fusion protein consisting of the Immunoglobulin Fc-region and any one polypeptide of claim 1.

10. An antibody immunospecific for the polypeptide of any one of claims 1 to 3.

10

11. A method for screening to identify compounds that stimulate or inhibit the function or level of the polypeptide of claim 1 comprising a method selected from the group consisting of:

15

(a) measuring or, detecting, quantitatively or qualitatively, the binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;

(b) measuring the competition of binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;

20

(c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes expressing the polypeptide;

25

(d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a control mixture which contains no candidate compound; or

(e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide or said polypeptide in cells, using for instance, an ELISA assay, and

30

(f) producing said compound according to biotechnological or chemical standard techniques.

THIS PAGE BLANK (USPTO)

1 / 2

Fig. 1






Fig. 2



THIS PAGE BLANK (USPTO)

Fig. 3

THIS PAGE BLANK (USPTO)

SEQUENCE LISTING

<110> Merck Patent GmbH

5 <120> Novel heparanase

<130> HSPnaseKDWS

<140>

10 <141>

<160> 2

<170> PatentIn Ver. 2.1

15

<210> 1

<211> 1779

<212> DNA

<213> Homo sapiens

20

<220>

<221> CDS

<222> (1)..(1779)

25 <400> 1

atg	agg	gtg	ctt	tgt	gcc	ttc	cct	gaa	gcc	atg	ccc	tcc	agc	aac	tcc	48
Met	Arg	Val	Leu	Cys	Ala	Phe	Pro	Glu	Ala	Met	Pro	Ser	Ser	Asn	Ser	
1				5					10					15		

cgc	ccc	ccc	gcg	tgc	cta	gcc	ccg	ggg	gct	ctc	tac	ttg	gct	ctg	ttg	96
Arg	Pro	Pro	Ala	Cys	Leu	Ala	Pro	Gly	Ala	Leu	Tyr	Leu	Ala	Leu	Leu	
			20					25					30			

ctc	cat	ctc	tcc	ctt	tcc	tcc	cag	gct	gga	gac	agg	aga	ccc	ttg	cct	144
Leu	His	Leu	Ser	Leu	Ser	Ser	Gln	Ala	Gly	Asp	Arg	Arg	Pro	Leu	Pro	
		35					40				45					

gta	gac	aga	gct	gca	ggt	ttg	aag	gaa	aag	acc	ctg	att	cta	ctt	gat	192
Val	Asp	Arg	Ala	Ala	Gly	Leu	Lys	Glu	Lys	Thr	Leu	Ile	Leu	Leu	Asp	
	50					55					60					

gtg	agc	acc	aag	aac	cca	gtc	agg	aca	gtc	aat	gag	aac	ttc	ctc	tct	240
Val	Ser	Thr	Lys	Asn	Pro	Val	Arg	Thr	Val	Asn	Glu	Asn	Phe	Leu	Ser	
	65				70				75					80		

ctg	cag	ctg	gat	ccg	tcc	atc	att	cat	gat	ggc	tgg	ctc	gat	ttc	cta	288
Leu	Gln	Leu	Asp	Pro	Ser	Ile	Ile	His	Asp	Gly	Trp	Leu	Asp	Phe	Leu	
			85						90					95		

agc	tcc	aag	cgc	ttg	gtg	acc	ctg	gcc	cgg	gga	ctt	tcg	ccc	gcc	ttt	336
Ser	Ser	Lys	Arg	Leu	Val	Thr	Leu	Ala	Arg	Gly	Leu	Ser	Pro	Ala	Phe	
			100					105					110			

ctg	cgc	ttc	ggg	ggc	aaa	agg	acc	gac	ttc	ctg	cag	ttc	cag	aac	ctg	384
Leu	Arg	Phe	Gly	Gly	Lys	Arg	Thr	Asp	Phe	Leu	Gln	Phe	Gln	Asn	Leu	
		115					120					125				

agg	aac	ccg	gcg	aaa	agc	cgc	ggg	ggc	ccg	ggc	ccg	gat	tac	tat	ctc	432
Arg	Asn	Pro	Ala	Lys	Ser	Arg	Gly	Gly	Pro	Gly	Pro	Asp	Tyr	Tyr	Leu	
		130					135				140					

60

THIS PAGE BLANK (USPTO)

	aaa aac tat gag gat gac att gtt cga agt gat gtt gcc tta gat aaa	480
	Lys Asn Tyr Glu Asp Asp Ile Val Arg Ser Asp Val Ala Leu Asp Lys	
	145 150 155 160	
5	cag aaa ggc tgc aag att gcc cag cac cct gat gtt atg ctg gtg ctc	528
	Gln Lys Gly Cys Lys Ile Ala Gln His Pro Asp Val Met Leu Val Leu	
	165 170 175	
10	caa agg gag aag gca gct cag atg cat ctg gtt ctt cta aag gag caa	576
	Gln Arg Glu Lys Ala Ala Gln Met His Leu Val Leu Leu Lys Glu Gln	
	180 185 190	
15	ttc tcc aat act tac agt aat ctc ata tta aca gcc agg tct cta gac	624
	Phe Ser Asn Thr Tyr Ser Asn Leu Ile Leu Thr Ala Arg Ser Leu Asp	
	195 200 205	
20	aaa ctt tat aac ttt gct gat tgc tct gga ctc cac ctg ata ttt gct	672
	Lys Leu Tyr Asn Phe Ala Asp Cys Ser Gly Leu His Leu Ile Phe Ala	
	210 215 220	
25	cta aat gca ctg cgt cgt aat ccc aat aac tcc tgg aac agt tct agt	720
	Leu Asn Ala Leu Arg Arg Asn Pro Asn Asn Ser Trp Asn Ser Ser Ser	
	225 230 235 240	
30	gcc ctg agt ctg ttg aag tac agc gcc agc aaa aag tac aac att tct	768
	Ala Leu Ser Leu Leu Lys Tyr Ser Ala Ser Lys Lys Tyr Asn Ile Ser	
	245 250 255	
35	tgg gaa ctg ggt aat gag cca aat aac tat cgg acc atg cat ggc cgg	816
	Trp Glu Leu Gly Asn Glu Pro Asn Asn Tyr Arg Thr Met His Gly Arg	
	260 265 270	
40	gca gta aat ggc agc cag ttg gga aag gat tac atc cag ctg aag agc	864
	Ala Val Asn Gly Ser Gln Leu Gly Lys Asp Tyr Ile Gln Leu Lys Ser	
	275 280 285	
45	ctg ttg cag ccc atc cgg att tat tcc aga gcc agc tta tat ggc cct	912
	Leu Leu Gln Pro Ile Arg Ile Tyr Ser Arg Ala Ser Leu Tyr Gly Pro	
	290 295 300	
50	aat att ggg cgg ccg agg aag aat gtc atc gcc ctc cta gat gga ttc	960
	Asn Ile Gly Arg Pro Arg Lys Asn Val Ile Ala Leu Leu Asp Gly Phe	
	305 310 315 320	
55	atg aag gtg gca gga agt aca gta gat gca gtt acc tgg caa cat tgc	1008
	Met Lys Val Ala Gly Ser Thr Val Asp Ala Val Thr Trp Gln His Cys	
	325 330 335	
60	tac att gat ggc cgg gtg gtc aag gtg atg gac ttc ctg aaa act cgc	1056
	Tyr Ile Asp Gly Arg Val Val Lys Val Met Asp Phe Leu Lys Thr Arg	
	340 345 350	
65	ctg tta gac aca ctc tct gac cag att agg aaa att cag aaa gtg gtt	1104
	Leu Leu Asp Thr Leu Ser Asp Gln Ile Arg Lys Ile Gln Lys Val Val	
	355 360 365	
70	aat aca tac act cca gga aag aag att tgg ctt gaa ggt gtg gtg acc	1152
	Asn Thr Tyr Thr Pro Gly Lys Lys Ile Trp Leu Glu Gly Val Val Thr	
	370 375 380	
75	acc tca gct gga ggc aca aac aat cta tcc gat tcc tat gct gca gga	1200

THIS PAGE BLANK (USPTO)

3

	Thr	Ser	Ala	Gly	Gly	Thr	Asn	Asn	Leu	Ser	Asp	Ser	Tyr	Ala	Ala	Gly	
	385					390					395					400	
5	ttc	tta	tgg	ttg	aac	act	tta	gga	atg	ctg	gcc	aat	cag	ggc	att	gat	1248
	Phe	Leu	Trp	Leu	Asn	Thr	Leu	Gly	Met	Leu	Ala	Asn	Gln	Gly	Ile	Asp	
					405					410					415		
10	gtc	gtg	ata	cgg	cac	tca	ttt	ttt	gac	cat	gga	tac	aat	cac	ctc	gtg	1296
	Val	Val	Ile	Arg	His	Ser	Phe	Phe	Asp	His	Gly	Tyr	Asn	His	Leu	Val	
				420					425					430			
15	gac	cag	aat	ttt	aac	cca	tta	cca	gac	tac	tgg	ctc	tct	ctc	ctc	tac	1344
	Asp	Gln	Asn	Phe	Asn	Pro	Leu	Pro	Asp	Tyr	Trp	Leu	Ser	Leu	Leu	Tyr	
				435				440					445				
20	aag	cgc	ctg	atc	ggc	ccc	aaa	gtc	ttg	gct	gtg	cat	gtg	gct	ggg	ctc	1392
	Lys	Arg	Leu	Ile	Gly	Pro	Lys	Val	Leu	Ala	Val	His	Val	Ala	Gly	Leu	
		450					455					460					
25	cag	cgg	aag	cca	cgg	cct	ggc	cga	gtg	atc	cgg	gac	aaa	cta	agg	att	1440
	Gln	Arg	Lys	Pro	Arg	Pro	Gly	Arg	Val	Ile	Arg	Asp	Lys	Leu	Arg	Ile	
	465					470					475				480		
30	tat	gct	cac	tgc	aca	aac	cac	cac	aac	cac	aac	tac	gtt	cgt	ggg	tcc	1488
	Tyr	Ala	His	Cys	Thr	Asn	His	His	Asn	His	Asn	Tyr	Val	Arg	Gly	Ser	
					485				490						495		
35	att	aca	ctt	ttt	atc	atc	aac	ttg	cat	cga	tca	aga	aag	aaa	atc	aag	1536
	Ile	Thr	Leu	Phe	Ile	Ile	Asn	Leu	His	Arg	Ser	Arg	Lys	Lys	Ile	Lys	
				500					505					510			
40	ctg	gct	ggg	act	ctc	aga	gac	aag	ctg	gtt	cac	cag	tac	ctg	ctg	cag	1584
	Leu	Ala	Gly	Thr	Leu	Arg	Asp	Lys	Leu	Val	His	Gln	Tyr	Leu	Leu	Gln	
			515					520					525				
45	ccc	tat	ggg	cag	gag	ggc	cta	aag	tcc	aag	tca	gtg	caa	ctg	aat	ggc	1632
	Pro	Tyr	Gly	Gln	Glu	Gly	Leu	Lys	Ser	Lys	Ser	Val	Gln	Leu	Asn	Gly	
		530					535					540					
50	cag	ccc	tta	gtg	atg	gtg	gac	gac	ggg	acc	ctc	cca	gaa	ttg	aag	ccc	1680
	Gln	Pro	Leu	Val	Met	Val	Asp	Asp	Gly	Thr	Leu	Pro	Glu	Leu	Lys	Pro	
	545					550					55						

THIS PAGE BLANK (USP 10)

	Met	Arg	Val	Leu	Cys	Ala	Phe	Pro	Glu	Ala	Met	Pro	Ser	Ser	Asn	Ser
	1				5					10					15	
	Arg	Pro	Pro	Ala	Cys	Leu	Ala	Pro	Gly	Ala	Leu	Tyr	Leu	Ala	Leu	Leu
				20					25					30		
5	Leu	His	Leu	Ser	Leu	Ser	Ser	Gln	Ala	Gly	Asp	Arg	Arg	Pro	Leu	Pro
		35						40					45			
	Val	Asp	Arg	Ala	Ala	Gly	Leu	Lys	Glu	Lys	Thr	Leu	Ile	Leu	Leu	Asp
	50						55					60				
	Val	Ser	Thr	Lys	Asn	Pro	Val	Arg	Thr	Val	Asn	Glu	Asn	Phe	Leu	Ser
10	65					70					75					80
	Leu	Gln	Leu	Asp	Pro	Ser	Ile	Ile	His	Asp	Gly	Trp	Leu	Asp	Phe	Leu
					85					90					95	
	Ser	Ser	Lys	Arg	Leu	Val	Thr	Leu	Ala	Arg	Gly	Leu	Ser	Pro	Ala	Phe
				100					105					110		
15	Leu	Arg	Phe	Gly	Gly	Lys	Arg	Thr	Asp	Phe	Leu	Gln	Phe	Gln	Asn	Leu
		115						120					125			
	Arg	Asn	Pro	Ala	Lys	Ser	Arg	Gly	Gly	Pro	Gly	Pro	Asp	Tyr	Tyr	Leu
	130						135					140				
	Lys	Asn	Tyr	Glu	Asp	Asp	Ile	Val	Arg	Ser	Asp	Val	Ala	Leu	Asp	Lys
20	145					150					155					160
	Gln	Lys	Gly	Cys	Lys	Ile	Ala	Gln	His	Pro	Asp	Val	Met	Leu	Val	Leu
				165						170					175	
	Gln	Arg	Glu	Lys	Ala	Ala	Gln	Met	His	Leu	Val	Leu	Leu	Lys	Glu	Gln
				180					185					190		
25	Phe	Ser	Asn	Thr	Tyr	Ser	Asn	Leu	Ile	Leu	Thr	Ala	Arg	Ser	Leu	Asp
		195						200					205			
	Lys	Leu	Tyr	Asn	Phe	Ala	Asp	Cys	Ser	Gly	Leu	His	Leu	Ile	Phe	Ala
	210						215					220				
	Leu	Asn	Ala	Leu	Arg	Arg	Asn	Pro	Asn	Asn	Ser	Trp	Asn	Ser	Ser	Ser
30	225					230					235					240
	Ala	Leu	Ser	Leu	Leu	Lys	Tyr	Ser	Ala	Ser	Lys	Lys	Tyr	Asn	Ile	Ser
				245						250					255	
	Trp	Glu	Leu	Gly	Asn	Glu	Pro	Asn	Asn	Tyr	Arg	Thr	Met	His	Gly	Arg
				260					265					270		
35	Ala	Val	Asn	Gly	Ser	Gln	Leu	Gly	Lys	Asp	Tyr	Ile	Gln	Leu	Lys	Ser
		275						280					285			
	Leu	Leu	Gln	Pro	Ile	Arg	Ile	Tyr	Ser	Arg	Ala	Ser	Leu	Tyr	Gly	Pro
	290						295					300				
	Asn	Ile	Gly	Arg	Pro	Arg	Lys	Asn	Val	Ile	Ala	Leu	Leu	Asp	Gly	Phe
40	305					310					315					320
	Met	Lys	Val	Ala	Gly	Ser	Thr	Val	Asp	Ala	Val	Thr	Trp	Gln	His	Cys
				325						330					335	
	Tyr	Ile	Asp	Gly	Arg	Val	Val	Lys	Val	Met	Asp	Phe	Leu	Lys	Thr	Arg
				340					345					350		
45	Leu	Leu	Asp	Thr	Leu	Ser	Asp	Gln	Ile	Arg	Lys	Ile	Gln	Lys	Val	Val
		355						360					365			
	Asn	Thr	Tyr	Thr	Pro	Gly	Lys	Lys	Ile	Trp	Leu	Glu	Gly	Val	Val	Thr
	370						375					380				
	Thr	Ser	Ala	Gly	Gly	Thr	Asn	Asn	Leu	Ser	Asp	Ser	Tyr	Ala	Ala	Gly
50	385					390					395					400
	Phe	Leu	Trp	Leu	Asn	Thr	Leu	Gly	Met	Leu	Ala	Asn	Gln	Gly	Ile	Asp
				405						410					415	
	Val	Val	Ile	Arg	His	Ser	Phe	Phe	Asp	His	Gly	Tyr	Asn	His	Leu	Val
				420					425					430		
55	Asp	Gln	Asn	Phe	Asn	Pro	Leu	Pro	Asp	Tyr	Trp	Leu	Ser	Leu	Leu	Tyr
		435						440					445			
	Lys	Arg	Leu	Ile	Gly	Pro	Lys	Val	Leu	Ala	Val	His	Val	Ala	Gly	Leu
	450						455					460				
	Gln	Arg	Lys	Pro	Arg	Pro	Gly	Arg	Val	Ile	Arg	Asp	Lys	Leu	Arg	Ile
60	465					470					475					480
	Tyr	Ala	His	Cys	Thr	Asn	His	His	Asn	His	Asn	Tyr	Val	Arg	Gly	Ser

THIS PAGE BLANK (USPTO)

5

				485					490					495
	Ile	Thr	Leu	Phe	Ile	Ile	Asn	Leu	His	Arg	Ser	Arg	Lys	Lys
				500					505				510	Ile
	Leu	Ala	Gly	Thr	Leu	Arg	Asp	Lys	Leu	Val	His	Gln	Tyr	Leu
5			515					520					525	Leu
	Pro	Tyr	Gly	Gln	Glu	Gly	Leu	Lys	Ser	Lys	Ser	Val	Gln	Leu
		530					535					540	Leu	Asn
	Gln	Pro	Leu	Val	Met	Val	Asp	Asp	Gly	Thr	Leu	Pro	Glu	Leu
	545					550					555			Lys
10	Arg	Pro	Leu	Arg	Ala	Gly	Arg	Thr	Leu	Val	Ile	Pro	Pro	Val
				565						570				Thr
	Gly	Phe	Tyr	Val	Val	Lys	Asn	Val	Asn	Ala	Leu	Ala	Cys	Arg
				580					585					Tyr
													590	Arg

15

THIS PAGE BLANK (USPTO)